TEVA - Why Allergan Stock Will Keep Falling
Allergan’s (AGN) fourth quarter earnings report put a quick end to the stock’s near-term rally. Despite CEO Brent Saunders trying to put a positive spin on the company’s prospects and against the generic competition it's about to face, investors headed for the exit. And with deep value on the share price and manageable debt levels on the balance sheet, what will it take for AGN stock to stop falling?
Q4 2018 Loss
Allergan reported a Q4 2018 GAAP loss of $12.83 but non-GAAP performance net income per share of $4.29. For full-year 2018,